Dare Bioscience Files S-1 for New Securities Offering

TL;DR

Dare Bioscience just filed an S-1, looks like they're raising cash. Keep an eye on this one.

AI Summary

Dare Bioscience, Inc. filed an S-1 registration statement on November 15, 2024, to register securities under the Securities Act of 1933. The company, formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc., is incorporated in Delaware and headquartered in San Diego, California. This filing indicates a potential offering of new securities, though specific details on the amount or terms are not yet provided in this excerpt.

Why It Matters

This S-1 filing signals Dare Bioscience's intent to raise capital, which could fund its pharmaceutical development pipeline and future operations.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant capital raises or stock offerings, which can introduce volatility and dilution risk for existing shareholders.

Key Numbers

• 333-283280 — SEC File Number (Identifies this specific registration statement with the SEC.)
• 20241115 — Filing Date (Date the S-1 was officially filed with the SEC.)

Key Players & Entities

• Dare Bioscience, Inc. (company) — Registrant
• Sabrina Martucci Johnson (person) — Chief Executive Officer
• Cerulean Pharma Inc. (company) — Former Company Name
• Tempo Pharmaceuticals Inc (company) — Former Company Name
• 3655 Nobel Drive, Suite 260 San Diego, California 92122 (address) — Principal Executive Offices
• 858-926-7655 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0 — 0 shares of our common stock, par value $0.0001, by Lincoln Park Capital Fund, LLC
• $3.57 — rted sale price of our common stock was $3.57 per share. Investing in our common st
• $15,000,000 — purchase from us up to an aggregate of $15,000,000 of our common stock (subject to certain
• $0.50 — price of our common stock is not below $0.50 per share, we may direct Lincoln Park t
• $5.00 — price of our common stock is not below $5.00 or $7.50, respectively, on the business
• $7 — our common stock is not below $5.00 or $7.50, respectively, on the business day o
• $500,000 — single Regular Purchase may not exceed $500,000. The purchase price per share for each
• $3.59 — he Purchase Agreement equals or exceeds $3.59 per share (which represents the lower o

Filing Documents

• forms-1.htm (S-1) — 681KB
• ex5-1.htm (EX-5.1) — 18KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 15KB
• forms-1_001.jpg (GRAPHIC) — 10KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-046346.txt ( ) — 743KB

Risk Factors

Risk Factors 8 Special Note Regarding Forward-Looking Statements 13 Our Agreements with Lincoln Park 16

Use of Proceeds

Use of Proceeds 22 Selling Stockholder 23

Dilution

Dilution 24 Plan of Distribution 25 Legal Matters 26 Experts 26 Where You Can Find More Information 27 Incorporation of Documents by Reference 27 ABOUT THIS PROSPECTUS This prospectus does not contain all of the information included in the registration statement of which this prospectus forms a part. For a more complete understanding of the offering of the securities described herein, you should refer to the registration statement, including its exhibits. You should carefully read this prospectus, any prospectus supplement or free writing prospectus that we subsequently authorize for use in connection with the offering of the securities described herein, the information and documents incorporated herein by reference and the additional information under the heading “Where You Can Find More Information” before making an investment decision. You should rely only on the information we have provided or incorporated by reference in this prospectus, or in any prospectus supplement or free writing prospectus that we subsequently authorize for use in connection with the offering of the securities described herein. Neither we, nor the selling stockholder, have authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus, or any related prospectus supplement or free writing prospectus, is accurate only as of the date set forth on the cover page of any such document or any earlier date as of which such information is given, as applicable, and that any information we have incorporated herein by reference is accurate only as of the date set forth on the cover page of any such document containing such information or any earlier date as of which such information is given, as applicable, regardless of the time of delivery of this prosp

View Full Filing

View this S-1 filing on SEC EDGAR